Efficient and reproducible generation of human iPSC-derived cardiomyocytes using a stirred bioreactor

Maksymilian Prondzynski,Raul H. Bortolin,Paul Berkson,Michael A. Trembley,Kevin Shani,Mason E. Sweat,Joshua Mayourian,Albert M. Cordoves,Nnaemeka J. Anyanwu,Yashasvi Tharani,Justin Cotton,Joseph B. Milosh,David Walker,Yan Zhang,Fujian Liu,Xujie Liu,Kevin K. Parker,Vassilios J. Bezzerides,William T. Pu

DOI: https://doi.org/10.1101/2024.02.24.581789

2024-02-28

Abstract:In the last decade human iPSC-derived cardiomyocytes (hiPSC-CMs) proved to be valuable for cardiac disease modeling and cardiac regeneration, yet challenges with scale, quality, inter-batch consistency, and cryopreservation remain, reducing experimental reproducibility and limiting clinical translation. Here, we report a robust cardiac differentiation protocol that uses Wnt modulation and a stirred suspension bioreactor to produce on average 124 million hiPSC-CMs with >90% purity using a variety of hiPSC lines (19 differentiations; 10 iPSC lines). After controlled freeze and thaw, bioreactor-derived CMs (bCMs) showed high viability (>90%), interbatch reproducibility in cellular morphology, function, drug response and ventricular identity, which was further supported by single cell transcriptomes. bCMs on microcontact printed substrates revealed a higher degree of sarcomere maturation and viability during long-term culture compared to monolayer-derived CMs (mCMs). Moreover, functional investigation of bCMs in 3D engineered heart tissues showed earlier and stronger force production during long-term culture, and robust pacing capture up to 4 Hz when compared to mCMs. bCMs derived from this differentiation protocol will expand the applications of hiPSC-CMs by providing a reproducible, scalable, and resource efficient method to generate cardiac cells with well-characterized structural and functional properties superior to standard mCMs.

Cell Biology

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is how to generate human - induced pluripotent stem cell - derived cardiomyocytes (hiPSC - CMs) efficiently and reproducibly. Specifically, the researchers face the following challenges:

1. **Scale and Quality**: Existing methods have difficulties in generating a large number of high - quality hiPSC - CMs.
2. **Inter - batch Consistency**: There are significant differences in cell quality and functional characteristics between different batches, which affect the reproducibility of experiments.
3. **Cell Function after Cryopreservation**: After thawing, the key functional characteristics such as contraction, electrophysiological characteristics and drug response of cryopreserved hiPSC - CMs will be affected.

To meet these challenges, the researchers developed a new cardiomyocyte differentiation protocol based on a stirred bioreactor. By optimizing the regulation of the Wnt signaling pathway and combining the use of a stirred - suspension bioreactor, this protocol has successfully achieved the following goals:

- **High Yield**: On average, each 100 - milliliter run can produce approximately 124 million hiPSC - CMs.
- **High Purity**: The purity of the generated hiPSC - CMs exceeds 90%.
- **High Reproducibility**: Cell morphology, function, drug response, and ventricular identity show a high degree of consistency between different batches.
- **Good Cryopreservation and Recovery Performance**: After thawing, the cryopreserved cells still maintain high viability (> 90%) and show better structural and functional maturity in long - term culture.

In addition, compared with cardiomyocytes (mCMs) derived from traditional monolayer culture, bioreactor - derived cardiomyocytes (bCMs) show higher sarcomere maturity and viability on micro - contact - printed substrates, and show stronger force - generation ability and faster contraction response in three - dimensional engineered heart tissues.

In summary, this study aims to provide a scalable, reproducible, and resource - efficient method for generating hiPSC - CMs through an improved cardiomyocyte differentiation method, thereby providing better tools and support for heart disease modeling and therapeutic cardiomyocyte replacement.